FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to a pharmaceutical composition for improved stability of anakinra, a method of treating eye disorders associated with IL-1 (versions), a drug delivery device. Pharmaceutical composition for improved stability of anakinra contains: anakinra, HEPES buffer or mixture of HEPES and sodium citrate, at least one osmolyte and sodium chloride. A method of treating eye disorders associated with IL-1 involves administering a therapeutically effective amount of a pharmaceutical composition for improved stability of anakinra. Device for drug delivery contains a pharmaceutical composition for improved stability of anakinra and represents a container, produced by blow-fill-seal technology.
EFFECT: group of inventions provides anakinra compositions with improved stability.
36 cl, 4 dwg, 13 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA | 2012 |
|
RU2599848C2 |
| COMPOSITION FOR RNA ADMINISTRATION | 2017 |
|
RU2746118C2 |
| COMBINED OPHTHALMIC AGENT | 2019 |
|
RU2733392C1 |
| PULMONARY SURFACTANT COMPOSITIONS AND METHODS OF USING THEM PROMOTING MUCUS ELIMINATION | 2007 |
|
RU2455021C2 |
| FORMULA FOR INTRODUCING RNA | 2019 |
|
RU2797147C2 |
| METHOD OF CONTROLLING MODIFICATION REACTION OF POLYPEPTIDE | 2009 |
|
RU2532850C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| DRUG FORM FOR hGH AND rhIGF-1 COMBINATION+ | 2010 |
|
RU2558821C2 |
| PHARMACEUTICAL COMPOSITIONS AND METHODS FOR APPLICATION OF 4-PREGNEN-11β-17-21-TRIOL-3,20-DIONE DERIVATIVES | 2012 |
|
RU2683775C2 |
| SUBSTITUTED GAMMA-LACTAMES AS THERAPEUTIC AGENTS | 2009 |
|
RU2543379C2 |
